for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Horizon Therapeutics PLC

HZNP.O

Latest Trade

30.26USD

Change

0.45(+1.51%)

Volume

1,255,796

Today's Range

29.38

 - 

30.36

52 Week Range

17.94

 - 

31.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
29.81
Open
29.88
Volume
1,255,796
3M AVG Volume
25.11
Today's High
30.36
Today's Low
29.38
52 Week High
31.25
52 Week Low
17.94
Shares Out (MIL)
187.30
Market Cap (MIL)
5,667.77
Forward P/E
16.25
Dividend (Yield %)
--

Next Event

Horizon Therapeutics PLC at Stifel Healthcare Conference

Latest Developments

More

Horizon Therapeutics Says FDA Has Granted Priority Review Of The Teprotumumab Biologics License Application For Treatment Of Active Thyroid Eye Disease

Horizon Therapeutics Comments On Court Of Appeals Decision On Vimovo Tablets

Horizon Therapeutics Announces U.S. FDA Acceptance Of Its NDA To Make Procysbi

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Horizon Therapeutics PLC

Horizon Therapeutics plc, formerly Horizon Pharma plc, is a rare disease biopharmaceutical company. The Company is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The Company markets approximately 10 medicines, of which 6 are for rare and rheumatic diseases. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Industry

Biotechnology & Drugs

Contact Info

Connaught House

1St Floor, 1 Burlington Road

+353.1.7722100

https://www.horizontherapeutics.com/

Executive Leadership

Timothy P. Walbert

Chairman of the Board, President, Chief Executive Officer

Paul W. Hoelscher

Chief Financial Officer, Executive Vice President

Irina P. Konstantinovsky

Chief Human Resource Officer, Executive Vice President

Barry J. Moze

Executive Vice President, Chief Administrative Officer

Shao-Lee Lin

Executive Vice President, Head of Research and Development, Chief Scientific Officer

Key Stats

1.60 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.0K

2017

1.1K

2018

1.2K

2019(E)

1.3K
EPS (USD)

2016

2.160

2017

1.180

2018

1.830

2019(E)

1.862
Price To Earnings (TTM)
157.93
Price To Sales (TTM)
4.39
Price To Book (MRQ)
3.63
Price To Cash Flow (TTM)
20.30
Total Debt To Equity (MRQ)
86.62
LT Debt To Equity (MRQ)
86.62
Return on Investment (TTM)
1.02
Return on Equity (TTM)
0.85

Latest News

Latest News

IN BRIEF: Fed Circuit shuts down Actavis generic for Horizon’s osteoarthritis drug

Actavis Laboratories UT cannot offer a generic version of Horizon Pharma’s Pennsaid 2% serum until one of the patents on it expires, the U.S. Court of Appeals for the Federal Circuit held Thursday.

Recordati to seek Canadian approval for kidney disease drug

Italy's Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which treats a rare kidney disease, in a potential blow to Horizon Pharma,, which makes the only drug approved for treatment in Canada.

BRIEF-Horizon Pharma Q1 Non-Gaap Earnings Per Share $0.03

* REPORTS STRONG FIRST-QUARTER 2018 ORPHAN AND RHEUMATOLOGY NET SALES GROWTH; INCREASES FULL-YEAR 2018 GUIDANCE AND ANNOUNCES NEW COMPANY OPERATING STRUCTURE TO ENHANCE FOCUS ON RARE DISEASES

BRIEF-AGC Biologics Enters Commercial Manufacturing Agreement With Horizon Pharma

* AGC BIOLOGICS SAYS ENTERS INTO COMMERCIAL MANUFACTURING AGREEMENT WITH HORIZON PHARMA PLC FOR COMMERCIAL SUPPLY OF TEPROTUMUMAB Source text for Eikon: Further company coverage:

BRIEF-Horizon Pharma PLC Announces Q4 Non-Gaap Earnings Per Share $0.29

* FULL-YEAR 2018 ADJUSTED EBITDA GUIDANCE OF $370 MILLION TO $395 MILLION

BRIEF-Horizon Pharma PLC Submits Supplemental NDA For Ravicti

* HORIZON PHARMA PLC SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR RAVICTI® (GLYCEROL PHENYLBUTYRATE) ORAL LIQUID TO EXPAND AGE RANGE TO INCLUDE NEWBORNS Source text for Eikon: Further company coverage:

Ex-Horizon Pharma employee claims she was fired for past whistleblowing

Horizon Pharma PLC is facing a lawsuit claiming it fired an employee for bringing a whistleblower lawsuit against her previous employer, another drug company, that resulted in a settlement with the U.S. Justice Department.

BRIEF-Paulson & Co Inc UPS SHARE STAKE IN HORIZON PHARMA PLC, CAESARS ENTERTAINMENT CORP

* PAULSON & CO INC TAKES SHARE STAKE OF 2 MILLION SHARES IN CENTURYLINK INC - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up